Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Harvard Bioscience Inc Market Cap
The Harvard Bioscience Inc (HBIO) share price is expected to increase by 117.01% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered HBIO. Price targets range from $5.5 at the low end to $7 at the high end. The current analyst consensus for HBIO is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
HBIO is a stock in Industrials which has been forecasted to be worth $6.25 as an average. On the higher end, the forecast price is $7 USD by Paul Knight from Keybanc and on the lower end HBIO is forecasted to be $5.5 by from .
These are the latest 20 analyst ratings of HBIO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Bruce Jackson Benchmark | Speculative Buy | $7 | Reiterates | Jun 22, 2023 |
| Bruce Jackson Benchmark | Buy | $7 | Maintains | Apr 26, 2023 |
| Paul Knight Keybanc | Overweight | $7 | Maintains | Apr 26, 2023 |
| Kenneth Bruce Benchmark | Buy | $4 | Reiterates | Mar 10, 2023 |
| Paul Knight Keybanc | Overweight | $5 | Maintains | Nov 9, 2022 |
| Paul Knight Keybanc | Overweight | $7 | Maintains | Aug 5, 2022 |
KeyBanc | Overweight | Initiates | Nov 10, 2020 | |
Keybanc | Overweight | Initiates | Nov 10, 2020 | |
| Bruce Jackson Benchmark | Speculative Buy | $4 | Maintains | Feb 27, 2020 |
Singular Research | Buy | Initiates | Nov 17, 2016 | |
Benchmark | Buy | Initiates | Jul 28, 2015 | |
Sidoti & Co. | Buy | Upgrade | Nov 26, 2013 |
When did it IPO
2000
Staff Count
391
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. James W. Green
Market Cap
$131.7M
In 2023, HBIO generated $112.3M in revenue, which was a decrease of -0.96% from the previous year. This can be seen as a signal that HBIO's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
